By Bhanvi Satija and Raghav Mahobe (Reuters) – Pfizer Inc on Tuesday reported higher-than-expected first-quarter revenue and profit, buoyed by demand for its COVID-19 products, and reaffirmed it[...]
Read more
Health
Zimmer Biomet raises annual forecasts on knees and hips unit strength
(Reuters) – Zimmer Biomet Holdings Inc raised its annual sales and profit forecasts on Tuesday, banking on strong demand for its knees and hips products amid a sustained recovery in surgical pro[...]
Read more
One-third of US nurses plan to quit profession – report
By Khushi Mandowara and Leroy Leo (Reuters) – Almost a third of the nurses in the United States are considering leaving their profession after the COVID-19 pandemic left them overwhelmed and fat[...]
Read more
Japan’s Astellas to buy Iveric Bio for $5.9 billion to expand eyesight treatments
By Rocky Swift TOKYO (Reuters) -Japan’s Astellas Pharma said on Monday it agreed to buy U.S. drugmaker Iveric Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a ran[...]
Read more
Pfizer pledge for more equal access to RSV shot faces hurdles
By Jennifer Rigby and Maggie Fick LONDON (Reuters) – Pfizer Inc has pledged to deliver critical new medicines more quickly in low-income nations, but its first such vaccine effort faces hurdles[...]
Read more
US FDA approves Pfizer’s next-generation pneumococcal vaccine
(Reuters) – The U.S. Food and Drug Administration (FDA) has approved Pfizer Inc’s next-generation vaccine to prevent pneumococcal disease in children aged six weeks to 17 years, the compan[...]
Read more
Fully booked! China braces for record May Day holiday rush
By Sophie Yu and Brenda Goh BEIJING (Reuters) – China is bracing for a record-high travel rush over the Labour Day holiday, with popular sightseeing spots selling out of tickets and some cities[...]
Read more
Drugmakers scout for deals, ramp up research spending
By Manas Mishra and Patrick Wingrove (Reuters) – Drugmakers including Merck & Co, AstraZeneca Plc and AbbVie Inc said on Thursday they are open to acquisitions and reported a ramp up in rese[...]
Read more
Gilead profit misses Wall Street expectations as COVID drug sales decline
(Reuters) -Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%[...]
Read more